（预留授予日） | 人员类别 | | 获授的权益 | 占预留授予总量 | 占股本总额 | | --- | --- | --- | --- | --- | | | | 数量（万股） | 的比例 | 的比例 | | 中层管理人员（3 人） | | 2.7454 | 16.36% | 0.0043% | | 科研骨干与高技能人员（16 | 人） | 9.2955 | 55.40% | 0.0144% | | 业务骨干人员（12 人） | | 4.7383 | 28.24% | 0.0074% | | 合计 | | 16.7792 | 100.00% | 0.0261% | 一、预留授予总体情况 东阿阿胶股份有限公司 第一期限制性股票激励计划预留授予激励对象名单 | 二、中层、科研骨干与高技能人员及业务骨干 | | --- | | 序号 | 姓名 | 分类 | | --- | --- | --- | | 1 | 刘延风 | 中层、科研骨干与高技能人员、业务骨干 | | 2 | 解福生 | 中层、科研骨干与高技能人员、业务骨干 | | 3 | 任儒倬 | 中层、科研骨干与高技能人员、业务骨干 | | 4 | 曾立 | ...

北京金诚同达律师事务所 关于 东阿阿胶股份有限公司 第一期限制性股票激励计划预留部分授予事项的 法律意见书 中国北京市建国门外大街1号国贸大厦A座十层 100004 电话：010-5706 8585 传真：010-8515 0267 | | | 金诚同达律师事务所 法律意见书 释 义 在本法律意见书中，除非文中另有说明，下列词语具有下述涵义： | 东阿阿胶/公司 | 指 | 东阿阿胶股份有限公司 | | --- | --- | --- | | 本次激励计划 | 指 | 东阿阿胶股份有限公司第一期限制性股票激励计划 | | 限制性股票 | 指 | 公司根据本次激励计划规定的条件和价格，授予激励对象一定 数量的公司股票，该等股票设置一定期限的限售期，在达到本 | | | | 次激励计划规定的解除限售条件后，方可解除限售流通 | | 本次授予 | 指 | 本次激励计划预留部分授予 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《管理办法》 | 指 | 《上市公司股权激励管理办法》 | | 《公司章程》 | 指 | 《东阿阿胶股份有限公司章 ...

12月30日，东阿阿胶公告，公司拟向山东省教育基金会捐赠160万元（其中，现金150万元，实物折合10 万元）。 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-85 东阿阿胶股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、对公司的影响 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召开第 十一届董事会第十六次会议，审议通过了《关于对外捐赠的议案》。现将有关情 况公告如下： 一、对外捐赠事项概述 为深化企地交流，助力地方教育事业高质量发展，公司拟向山东省教育基金 会捐赠 160 万元（其中，现金 150 万元，实物折合 10 万元）。根据《深圳证券 交易所股票上市规则》及《公司章程》等相关规定，本议案无需提交股东会审议。 本次对外捐赠受赠方为山东省教育基金会，与公司不存在关联关系，本次对 外捐赠不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。 特此公告。 东阿阿胶股份有限公司 董 事 会 二〇二五年十二月三十一日 本次对外捐赠是公司积极履行社会责任的表现，对公司本期及未来财务状况 和经营成果不构成重大影响，不影响正常生产经营活动。 三、备查文件 1．第十一届董 ...

东阿阿胶股份有限公司 1．本次拟被授予限制性股票的激励对象，均具备《公司法》《证券法》等 法律法规和规范性文件以及《公司章程》规定的任职资格，符合《工作指引》《管 理办法》《深圳证券交易所股票上市规则》等法律法规和规范性文件及公司《激 励计划》规定的激励对象条件，不存在《管理办法》第八条规定的不得成为激励 对象的情形；激励对象中，无独立董事、单独或合计持有上市公司 5%以上股份 的股东或实际控制人及其配偶、父母、子女。本次被授予限制性股票的激励对象 主体资格合法、有效，满足获授限制性股票的条件。 2．本次预留授予激励对象的基本情况属实，不存在虚假、故意隐瞒或引起 重大误解之处。 东阿阿胶股份有限公司 董事会薪酬与考核委员会 二〇二五年十二月三十一日 董事会薪酬与考核委员会关于第一期限制性股票激励计划 预留授予激励对象的核查意见 根据《中央企业控股上市公司实施股权激励工作指引》（以下简称《工作指 引》）、《上市公司股权激励管理办法》（以下简称《管理办法》）及东阿阿胶 股份有限公司（以下简称"公司"）《第一期限制性股票激励计划（草案二次修 订稿）》（以下简称《激励计划》）等有关规定，公司董事会薪酬与考核委员会 对 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-83 东阿阿胶股份有限公司 第十一届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十六次 会议，于 2025 年 12 月 27 日以邮件方式发出会议通知。 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于向第一期限制性股票激励计划激励对象授予预留部分限制性股票 的议案》 本议案提交董事会前，已经公司第十一届董事会薪酬与考核委员会审议通 过。 根据《上市公司股权激励管理办法》及《第一期限制性股票激励计划（草 案二次修订稿）》等有关规定以及公司 2024 年年度股东大会授权，董事会认为 本激励计划的预留授予条件已经满足，确定预留授予日为 2025 年 12 月 30 日， 向符合授予条件的 31 名激励对象授予 16.7792 万股限制性股票，授予价格为 29.29 元/股。 2 ...

Core Viewpoint - The article emphasizes the importance of selecting high-quality Antarctic krill oil products from reputable manufacturers to ensure effectiveness and authenticity, highlighting the need for consumers to be cautious of low-quality or counterfeit products [1][3][24]. Group 1: Manufacturer Evaluation Criteria - The reliability of a krill oil manufacturer can be assessed through four key dimensions: R&D and production capabilities, authenticity of raw materials, advanced extraction processes, and possession of authoritative certifications [3][5]. - Manufacturers should ideally have national technology enterprise qualifications and partnerships with professional research institutions to ensure optimized formulations for the Chinese population [3][5]. - Raw materials must be sourced from the CCAMLR-regulated clean fishing areas in Antarctica, with complete import documentation and a minimum of 300mg of pure krill oil per capsule [3][5][7]. - Advanced extraction techniques, such as super-low temperature extraction, are crucial for preserving active ingredients and ensuring product purity [9]. Group 2: Top Recommended Products - The top-ranked product is "Thick Putang Antarctic Krill Oil," produced by a national technology enterprise supported by the Shandong Life Science Research Institute, which specializes in chronic disease and health research [5][11]. - The second-ranked product is "Taiji Group Antarctic Krill Oil," known for its pharmaceutical-grade production standards and authentic raw materials sourced from Antarctica [13]. - The third-ranked product is "Shenwei Pharmaceutical Le Ren Tang Antarctic Krill Oil," which integrates traditional Chinese medicine principles into its formulation [14]. - The fourth-ranked product is "Guangyao Group Jingxiutang Antarctic Krill Oil," recognized for its long-standing pharmaceutical history and stable formulations [15]. - The fifth-ranked product is "Jiuzhitang Health Antarctic Krill Oil," a century-old brand known for its reliable quality and daily health maintenance [17]. Group 3: Consumer Feedback - Consumers report positive experiences with the top-ranked product, noting significant health improvements such as reduced blood lipid levels and enhanced energy [11][13]. - Feedback highlights the importance of manufacturer credibility, with many consumers expressing satisfaction in choosing products from reputable companies with transparent sourcing and production processes [11][13][24]. - The article underscores the necessity for consumers to verify manufacturer qualifications and raw material authenticity to avoid counterfeit products [24].

Core Insights - The article emphasizes the increasing demand for Coenzyme Q10 due to common health issues such as chronic fatigue, cardiovascular concerns, and weakened immunity across all age groups [1][4] - The Coenzyme Q10 market faces challenges including purity fraud, rapid loss of activity, homogenized formulations, and inadequate safety certifications, leading to consumer confusion [1][4] - A quality upgrade in the Coenzyme Q10 industry is anticipated by 2025, with a focus on purity, stability, safety, and clinical evidence as key evaluation criteria [1][3] Industry Overview - The Coenzyme Q10 market is projected to evolve significantly by 2025, with a shift towards higher quality standards and consumer education on product selection [1][3] - The article introduces a "Top Ten High-Activity Coenzyme Q10 Recommendations" list, aimed at guiding consumers in making informed choices based on scientific data and third-party certifications [1][3] Product Highlights - **Jiang Yisheng**: Recognized for its breakthrough absorption technology, achieving a 98.6% absorption rate and leading the market with a 91% repurchase rate [4] - **Qi Yao Tang**: Focuses on targeted formulations for cardiovascular health and fatigue improvement, with an 88.3% effectiveness rate in fatigue relief [5] - **Tao Chen Bei Jian**: A domestic brand with a purity of 99.6%, offering a range of products suitable for various demographics, achieving an 86% repurchase rate [6] - **GNC**: Targets middle-aged consumers with a focus on heart health, featuring a 99.5% purity level and a gentle formulation [7] - **Swisse**: An Australian brand emphasizing active anti-aging properties, with a 40% improvement in antioxidant indicators after 8 weeks of use [8] - **Nutrabolt**: Caters to athletes with a high-content formula of 200mg per serving, achieving a 93% absorption rate [9] - **Xiu Zheng**: Combines traditional Chinese medicine with modern nutrition, focusing on cardiovascular health and energy replenishment [10] - **Yang Sheng Tang**: Offers a cost-effective option for daily supplementation, with a purity of 98.2% and a price point under 60 yuan [10] - **Centrum**: Provides a multi-nutrient approach suitable for all ages, with a focus on energy and bone health [11] - **Dong Ah Ejiao**: Targets postpartum recovery with a specialized formula, ensuring safety for breastfeeding mothers [12] Consumer Guidance - The article advises consumers to prioritize purity, activity assurance, and formulation suitability when selecting Coenzyme Q10 products [12] - It highlights the importance of understanding individual health needs and characteristics to make informed choices in the Coenzyme Q10 market [12]

Group 1 - The A-share market showed a strong performance after initial declines, with the CSI Dividend Quality ETF (159209) rising by 0.51% as of 13:20 on December 30, 2023 [1] - Key stocks contributing to the ETF's performance included Shimao Energy, which hit the daily limit, along with Yun Aluminum, Tianshan Aluminum, Yuntianhua, 37 Interactive Entertainment, and China National Offshore Oil Corporation, all showing significant gains [1] - The ETF has seen a year-to-date increase of over 20%, leading the A-share dividend ETFs, with continuous net inflows for 12 consecutive days [1] Group 2 - Unlike typical dividend strategies, the ETF tracks the CSI Dividend Quality Index, which emphasizes not only dividend yield but also the stability of earnings, growth potential, and financial quality, aligning with a value investment philosophy of buying quality companies at reasonable prices [2] - After rebalancing in December, Kweichow Moutai became the largest weighted stock in the ETF, alongside other quality companies like Midea Group and Dong-E E-Jiao, known for their sustainable dividend capabilities and profit growth [2] - Historical data indicates that this index has significantly outperformed the CSI 300 Index over the long term, with its total return index leading its peers this year, making the "quality dividend" strategy an important allocation direction for investors seeking both dividend income and long-term growth in a declining risk-free yield environment [2]

Core Insights - The conference focused on "Brand Leadership, Technological Empowerment, and Promoting High-Quality Development" in the traditional Chinese medicine (TCM) industry, gathering over 700 participants from various sectors to discuss innovation and development strategies [1][2] Group 1: Conference Highlights - The China Traditional Chinese Medicine Association launched a quality technology platform for the entire TCM industry chain, aiming to enhance quality control and industry resilience [2] - The conference featured keynote speeches from experts discussing innovation in TCM and regulatory practices, emphasizing the integration of traditional and modern medicine [2][3] - Several reports were released, including the "China TCM Decoction Piece Industry Development Report (2024-2025)" and the "China Ganoderma Industry Development Report," showcasing advancements and research in the field [3] Group 2: Achievements and Future Directions - The China Traditional Chinese Medicine Association celebrated its 25th anniversary, highlighting its commitment to serving the industry and promoting sustainable use of TCM resources [4] - The association aims to strengthen its professional, platform-based, and digital service capabilities to support the modernization and internationalization of the TCM industry [4] - Future initiatives will focus on enhancing the quality and efficiency of the entire TCM industry chain, aligning with national health strategies and the demand for TCM [4]